NasdaqGS - Nasdaq Real Time Price USD

Collegium Pharmaceutical, Inc. (COLL)

Compare

32.91

-0.43

(-1.29%)

At close: January 10 at 4:00:02 PM EST

31.89

-1.02

(-3.10%)

After hours: January 10 at 5:28:55 PM EST

Collegium Pharmaceutical Unveils 2025 Financial Projections

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue. The company completed the integration of Ironshore Therapeutics and plans targeted investments in Jornay PM to drive growth, aiming for significant top- and bottom-line growth and long-term shareholder value. More about Collegium

TipRanks 3 days ago

COLL
-1.29%
Collegium Provides 2025 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. “In 20

GlobeNewswire 4 days ago

COLL
-1.29%
Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Collegium Pharmaceutical, Inc. ( NASDAQ:COLL ) shareholders might be concerned after seeing the share price drop 22% in...

Simply Wall St. 18 days ago

COLL
-1.29%
Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) earnings announcement last week was disappointing for investors...

Simply Wall St. last month

COLL
-1.29%
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

COLL
-1.29%
JAZZ
Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences: Jefferies London Healthcare ConferenceFireside Chat Date and Time: Tuesday, November 19, 2024, at 1:30 p.m. GMT Piper Sandler 36th Annual Healthcare ConferenceFireside Chat D

GlobeNewswire last month

COLL
-1.29%
Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Collegium Pharmaceutical ( NASDAQ:COLL ) Third Quarter 2024 Results Key Financial Results Revenue: US$159.3m (up 17...

Simply Wall St. 2 months ago

COLL
-1.29%
Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Collegium Pharmaceutical Inc (COLL) reports a 17% increase in total net product revenues and outlines strategic plans for growth in the ADHD market.

GuruFocus.com 2 months ago

COLL
-1.29%
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

Zacks 2 months ago

COLL
-1.29%
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks 2 months ago

COLL
-1.29%
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -3.01% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

COLL
-1.29%
Collegium Pharmaceutical: Q3 Earnings Snapshot

COLL) on Thursday reported third-quarter earnings of $9.3 million. On a per-share basis, the Stoughton, Massachusetts-based company said it had profit of 27 cents. Earnings, adjusted for one-time gains and costs, came to $1.61 per share.

Associated Press Finance 2 months ago

COLL
-1.29%
Collegium Reports Record Third Quarter 2024 Financial Results

– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3’24 GAAP Net Income of $9.3 Million – – Delivered Record Q3’24 Adjusted EBITDA of $105.1 Million, Up 18% Year-over-Year – – Closed Acquisition of Ironshore Therapeutics, Establishing Presence in Neurology (ADHD) – – Appointed Vikram Karnani as Chief Executive Officer of Collegium – – Conference Call Schedu

GlobeNewswire 2 months ago

COLL
-1.29%
Collegium Appoints Vikram Karnani as Chief Executive Officer

Vikram Karnani is a Proven Industry Leader with Extensive Experience Growing Commercial Biopharmaceutical BusinessesSTOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that Vikram Karnani has been appointed as President and Chief Executive Officer (CEO) of Collegium and will join its Board of Dire

GlobeNewswire 2 months ago

COLL
-1.29%
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

COLL
-1.29%
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.

Zacks 2 months ago

COLL
-1.29%
PFE

NVO
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 2 months ago

COLL
-1.29%
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Inf

GlobeNewswire 2 months ago

COLL
-1.29%
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 2 months ago

COLL
-1.29%
Collegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Collegium Pharmaceutical Inc (COLL) reports a 7% increase in net product revenues and outlines strategic moves to enhance its portfolio and market position.

GuruFocus.com 3 months ago

COLL
-1.29%

Performance Overview

Return	COLL	S&P 500
YTD	+15.03%	-1.35%
1-Year	+1.95%	+22.51%
3-Year	+71.23%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceutical Unveils 2025 Financial Projections

Collegium Provides 2025 Financial Guidance and Business Update

Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus

Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Collegium to Participate in Upcoming Investor Conferences

Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Collegium Pharmaceutical: Q3 Earnings Snapshot

Collegium Reports Record Third Quarter 2024 Financial Results

Collegium Appoints Vikram Karnani as Chief Executive Officer

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?

Collegium Pharmaceutical Inc (COLL) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Performance Overview